Targeting specific immune cells to slow down cystic kidney disease
Targeting kidney resident macrophage niche filling to slow cystic kidney disease
This study is looking at how certain immune cells in the kidneys affect cystic kidney disease and is exploring a new way to target these cells to help manage the disease without harming their important functions, all with the goal of finding a better treatment for people living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-10861001 on NIH RePORTER |
What this research studies
This research investigates how kidney resident macrophages (KRM) contribute to cystic kidney disease and explores a new approach to selectively target these cells without affecting their essential functions in the body. The study aims to understand the mechanisms behind the replenishment of these macrophages after temporary depletion and how this relates to the progression of cyst growth. By using mouse models and examining the role of specific genes, the researchers hope to develop a targeted therapy that can provide long-term benefits for patients suffering from this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cystic kidney disease who may benefit from targeted therapies aimed at their specific immune cell populations.
Not a fit: Patients without cystic kidney disease or those with advanced kidney failure may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that slows the progression of cystic kidney disease, improving patient outcomes and quality of life.
How similar studies have performed: While targeting immune cells in kidney diseases is a relatively novel approach, preliminary data suggest that similar strategies have shown promise in animal models.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Zimmerman, Kurt a — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Zimmerman, Kurt a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.